Mina Nakagawa

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Matrix stiffness shapes early transcriptional trajectories during hepatic stellate cell activation.

Matrix stiffness shapes early transcriptional trajectories during hepatic stellate cell activation.

Journal: Hepatology international

Published: March 26, 2026

Cachexia in Cirrhosis Is Characterized by Sex-Specific Loss of Muscle Mass and Adipose Tissue.

Cachexia in Cirrhosis Is Characterized by Sex-Specific Loss of Muscle Mass and Adipose Tissue.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 14, 2025

Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study.

Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study.

Journal: Biomarker research

Published: July 09, 2025

Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis.

Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: June 30, 2025

Genetic alterations in hepatocellular carcinoma after sustained virological response in relation to the molecular characterization of metabolic diseases.

Genetic alterations in hepatocellular carcinoma after sustained virological response in relation to the molecular characterization of metabolic diseases.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 09, 2025

Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series.

Immune-related adverse events in patients with low baseline serum IL-6 treated with durvalumab plus tremelimumab for hepatocellular carcinoma: a case series.

Journal: Clinical journal of gastroenterology

Published: May 02, 2025

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Hepatology international

Published: April 30, 2025

Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study.

Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study.

Journal: Cancer medicine

Published: March 31, 2025

Cachexia is an independent predictor of mortality in patients with cirrhosis.

Cachexia is an independent predictor of mortality in patients with cirrhosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: December 20, 2024

Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids.

Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids.

Journal: Stem cell reports

Published: December 06, 2024

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

Journal: JHEP reports : innovation in hepatology

Published: August 04, 2024

High serum gamma-glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma.

High serum gamma-glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: April 03, 2024

Showing 1-12 of 61

Last Updated: 09/26/2026